Literature DB >> 17027978

Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines.

Akihisa Fukumoto1, Kiichiro Tomoda, Noriko Yoneda-Kato, Yoshiyuki Nakajima, Jun-ya Kato.   

Abstract

Jab1 overexpression is observed in many human cancers, but its physiological significance remains to be investigated. We reduced the level of Jab1 expression in pancreatic cancer cell lines, MIA PaCa-2 and PANC-1 by the RNA interference and found that Jab1-knockdown resulted in impaired cell proliferation and enhanced apoptosis regardless of the genotype of the tumor suppressor p53. This growth inhibition was rescued by the introduction of siRNA-resistant mouse Jab1 cDNA. Jab1-knocked-down cells expressed a higher level of c-myc, and additional depletion of c-myc rescued cells from Jab1-knockdown-mediated growth suppression. Thus, Jab1 overexpression contributes to pancreatic cancer cell proliferation and survival. Jab1 could be a novel target in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027978     DOI: 10.1016/j.febslet.2006.09.042

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Role of p97/Valosin-containing protein (VCP) and Jab1/CSN5 in testicular ischaemia-reperfusion injury.

Authors:  Sevil Cayli; Seda Ocakli; Ufuk Senel; Nilnur Eyerci; Tuncay Delibasi
Journal:  J Mol Histol       Date:  2016-01-11       Impact factor: 2.611

Review 2.  The emerging roles of Jab1/CSN5 in cancer.

Authors:  Lin Wang; Jun-Nian Zheng; Dong-Sheng Pei
Journal:  Med Oncol       Date:  2016-07-13       Impact factor: 3.064

3.  Stable form of JAB1 enhances proliferation and maintenance of hematopoietic progenitors.

Authors:  Masaaki Mori; Noriko Yoneda-Kato; Akihiro Yoshida; Jun-ya Kato
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

4.  COP9 signalosome subunit Csn8 is involved in maintaining proper duration of the G1 phase.

Authors:  Cheng Liu; Li-Quan Guo; Suchithra Menon; Dan Jin; Elah Pick; Xuejun Wang; Xing Wang Deng; Ning Wei
Journal:  J Biol Chem       Date:  2013-05-20       Impact factor: 5.157

5.  Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival.

Authors:  Hyung-Mun Yun; Ja-Hyun Baik; Insug Kang; Changbae Jin; Hyewhon Rhim
Journal:  J Biol Chem       Date:  2010-01-21       Impact factor: 5.157

6.  CSN5/JAB1 interacts with the centromeric components CENP-T and CENP-W and regulates their proteasome-mediated degradation.

Authors:  Younghwa Chun; Miae Lee; Byoungwoo Park; Soojin Lee
Journal:  J Biol Chem       Date:  2013-08-07       Impact factor: 5.157

Review 7.  Targeting Jab1/CSN5 in nasopharyngeal carcinoma.

Authors:  Yunbao Pan; Francois X Claret
Journal:  Cancer Lett       Date:  2012-08-04       Impact factor: 8.679

8.  CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression.

Authors:  Adam S Adler; Laurie E Littlepage; Meihong Lin; Tiara L A Kawahara; David J Wong; Zena Werb; Howard Y Chang
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

9.  Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.

Authors:  Y-H Lee; A D Judge; D Seo; M Kitade; L E Gómez-Quiroz; T Ishikawa; J B Andersen; B-K Kim; J U Marquardt; C Raggi; I Avital; E A Conner; I MacLachlan; V M Factor; S S Thorgeirsson
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

10.  CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner.

Authors:  Akihiro Yoshida; Noriko Yoneda-Kato; Jun-ya Kato
Journal:  Sci Rep       Date:  2013-01-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.